Rosaceiform eruption induced by erlotinib.
Adverse events with anti-epidermal growth factor receptor therapy mainly involve the skin. The most common cutaneous adverse event is an acneiform eruption, which occurs in more than 50% of cases. The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.
Patrizi
Annalisa
A
Department of Specialistic and Experimental Clinical Medicine, Division of Dermatology, University of Bologna, Italy. annalisa.patrizi@unibo.it
Bianchi
Federica
F
Neri
Iria
I
D017486:Acneiform Eruptions / Q000139:chemically induced; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride